Entera Bio (NASDAQ:ENTX – Get Free Report) and Inhibikase Therapeutics (NYSE:IKT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Insider & Institutional Ownership
14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 10.9% of Entera Bio shares are owned by company insiders. Comparatively, 14.7% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Entera Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Entera Bio | 0 | 0 | 1 | 0 | 3.00 |
| Inhibikase Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Entera Bio presently has a consensus target price of $10.00, suggesting a potential upside of 431.91%. Inhibikase Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 1,011.11%. Given Inhibikase Therapeutics’ higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Entera Bio.
Profitability
This table compares Entera Bio and Inhibikase Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Entera Bio | N/A | -100.37% | -84.09% |
| Inhibikase Therapeutics | N/A | -194.17% | -140.64% |
Earnings and Valuation
This table compares Entera Bio and Inhibikase Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Entera Bio | $57,000.00 | 1,180.28 | -$8.89 million | ($0.28) | -6.71 |
| Inhibikase Therapeutics | $260,000.00 | 38.73 | -$19.03 million | ($3.33) | -0.41 |
Entera Bio has higher earnings, but lower revenue than Inhibikase Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Entera Bio beats Inhibikase Therapeutics on 7 of the 11 factors compared between the two stocks.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
About Inhibikase Therapeutics
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.
